Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Magnus Brisander is active.

Publication


Featured researches published by Magnus Brisander.


International Journal of Pharmaceutics | 2015

Matrix effects in nilotinib formulations with pH-responsive polymer produced by carbon dioxide-mediated precipitation.

Stefano Colombo; Magnus Brisander; Jakob Haglöf; Peter Sjövall; Per Andersson; Jesper Østergaard; Martin Malmsten

Factors determining the pH-controlled dissolution kinetics of nilotinib formulations with the pH-titrable polymer hydroxypropyl methylcellulose phthalate, obtained by carbon dioxide-mediated precipitation, were mechanistically examined in acid and neutral environment. The matrix effect, modulating the drug dissolution, was characterized with a battery of physicochemical methodologies, including ToF-SIMS for surface composition, SAXS/WAXS and modulated DSC for crystallization characterization, and simultaneous UV-imaging and Raman spectroscopy for monitoring the dissolution process in detail. The hybrid particle formulations investigated consisted of amorphous nilotinib embedded in a polymer matrix in single continuous phase, displaying extended retained amorphicity also under wet conditions. It was demonstrated by Raman and FTIR spectroscopy that the efficient drug dispersion and amorphization in the polymer matrix were mediated by hydrogen bonding between the drug and the phthalate groups on the polymer. Simultaneous Raman and UV-imaging studies of the effect of drug load on the swelling and dissolution of the polymer matrix revealed that high nilotinib load prevented matrix swelling on passage from acid to neutral pH, thereby preventing re-precipitation and re-crystallization of incorporated nilotinib. These findings provide a mechanistic foundation of formulation development of nilotinib and other protein kinase inhibitors, which are now witnessing an intense therapeutic and industrial attention due to the difficulty in formulating these compounds so that efficient oral bioavailability is reached.


Pharmaceutical Research | 2014

Carbon Dioxide-Mediated Generation of Hybrid Nanoparticles for Improved Bioavailability of Protein Kinase Inhibitors

Gérald Jesson; Magnus Brisander; Per Andersson; Mustafa Demirbüker; Helene Derand; Hans Lennernäs; Martin Malmsten


Archive | 2013

A METHOD FOR PRODUCING STABLE, AMORPHOUS HYBRID NANOPARTICLES COMPRISING AT LEAST ONE PROTEIN KINASE INHIBITOR AND AT LEAST ONE POLYMERIC STABILIZING AND MATRIX- FORMING COMPONENT.

Magnus Brisander; Mustafa Demirbüker; Gérald Jesson; Martin Malmsten; Helene Derand


Archive | 2013

PHARMACEUTICAL COMPOSITION COMPRISING STABLE, AMORPHOUS, HYBRID NANOPARTICLES OF AT LEAST ONE PROTEIN KINASE INHIBITOR AND AT LEAST ONE POLYMERIC STABILIZING AND MATRIX-FORMING COMPONENT

Magnus Brisander; Mustafa Demirbüker; Gérald Jesson; Martin Malmsten; Helene Derand


Archive | 2013

Pharmaceutical compositions comprising ambrisentan and solid dispersion particles containing tadalafil

Gérald Jesson; Mustafa Demirbüker; Magnus Brisander


Archive | 2013

Pharmaceutical compositions comprising solid dispersion particles containing tadalafil

Gérald Jesson; Mustafa Demirbüker; Magnus Brisander; Anders Ringberg


Archive | 2017

preparações de tiotrópio

Gérald Jesson; Magnus Brisander; Mustafa Demirbueker


Archive | 2013

Pharmazeutische zusammensetzung mit stabilen amorphen hybridnanopartikeln aus mindestens einem kinasehemmer und mindestens einer polymeren stabilisierungs- und matrixbildungskomponente

Magnus Brisander; Mustafa Demirbüker; Gérald Jesson; Martin Malmsten; Helene Derand


Archive | 2013

Procédé de production de nanoparticules hybrides amorphes stables comprenant au moins un inhibiteur de la protéine kinase et au moins un constituant polymère stabilisant et matriciel

Magnus Brisander; Mustafa Demirbüker; Gérald Jesson; Martin Malmsten; Helene Derand


Archive | 2013

Compositions pharmaceutiques comprenant de l'ambrisentan et des particules de dispersion solide contenant du tadalafil

Gérald Jesson; Mustafa Demirbüker; Magnus Brisander

Collaboration


Dive into the Magnus Brisander's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Peter Sjövall

SP Technical Research Institute of Sweden

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge